Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application

1 Nov 2023

Abstract excerpt

Patients with biliary tract cancer (BTC) show different responses to chemotherapy, and there is no effective way to predict chemotherapeutic response. We have generated 61 BTC patient-derived organoids (PDOs) from 82 tumors (74.4%) that show similar histological and genetic characteristics to the corresponding primary BTC tissues. BTC tumor tissues with enhanced stemness- and proliferation-related gene expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37944531
DOI: 10.1016/j.xcrm.2023.101277

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical applicationPMID 37944531Read ↗

Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoidsSemantic proximity Read ↗

Establishment and Drug Screening of Patient-Derived Extrahepatic Biliary Tract Carcinoma OrganoidsSemantic proximity Read ↗

Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft.Semantic proximity Read ↗

The Origin of Patient-Derived Cancer Organoids from Pathologically Undiagnosed Specimen in Patients with Pancreatobiliary CancersSemantic proximity Read ↗

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.Semantic proximity Read ↗

Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancerSemantic proximity Read ↗

Translating cancer genomics for precision oncology in biliary tract cancers.Semantic proximity Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.Semantic proximity Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Efficient Establishment of Bile-Derived Organoids From Biliary Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.